CA A Cancer Journal for Clinicians· 2018Q1
Ovarian cancer statistics, 2018
- 3,732citations
- Q1SCImago
- 2018year
Short summary
In 2018, the US expects 22,240 new ovarian cancer cases and 14,070 deaths, with incidence and mortality rates declining significantly since the mid-1980s.
AI-generated from the title and abstract; the full text is not read.
Key points
- US ovarian cancer incidence projected at 22,240 cases and mortality at 14,070 deaths for 2018.
- Overall incidence declined 29% (1985-2014) and mortality declined 33% (1976-2015).
- Late-stage diagnosis (Stage III/IV) is common (80% of serous carcinomas), with low 5-year survival (42% and 26% respectively).
- Racial disparities in survival are stark, with Black women having the lowest survival rates across most stages and subtypes.
AI-generated from the title and abstract; the full text is not read.
Abstract
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.
The authors' abstract, as published at the source. CA A Cancer Journal for Clinicians, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Reproductive Medicine
Reproductive MedicineMedicine